Due to advancements spurred by AI/ML, the impact of digital health technology will grow. Data from the Department for Promotion of Industry and Internal Trade show that FDI in the medicines and ...

In the latest trading session, Pfizer (PFE) closed at $22.15, marking a +0.48% move from the previous day. The stock exceeded the S&P 500, which registered a gain of 0.13% for the day. On the other ...

We recently published a list of 15 Best Large-Cap Value Stocks to Buy as the Recession Hits. In this article, we are going to take a look at where Pfizer Inc. (NYSE:PFE) stands against other best ...

Pfizer's strong R&D pipeline, 7.5%+ dividend yield, & undervalued PE ratio make PFE stock a compelling investment opportunity ...

The market is characterized by trends such as personalized medicine, targeted therapies, and combination treatments. Key players include Eli Lilly, Bristol Myers Squibb, and AstraZeneca. As North ...

Tuesday was a relatively uneventful news day for Pfizer, especially following the pharmaceutical giant's disclosure on Monday ...

Discover how Viking Therapeutics, Inc.'s VK2735 and VK2809 target obesity and NASH markets. Click for my updated look at VKTX ...

Its statement also suggested the patient’s liver enzymes were elevated. That often is indicative of damage to cells in the organ, according to the Cleveland Clinic. Pfizer told CNBC that the trial ...

Pfizer Inc. (PFE) is currently at $22.83, up $0.71 or 3.19% --Would be highest close since April 4, 2025, when it closed at $22.97 --On pace for largest percent increase since Dec. 17, 2024, when it ...

Pfizer (NYSE: PFE) recently reminded investors how risky the drug-development business can be. On April 14, the company told investors it would scrap development of danuglipron, its oral GLP-1 ...

TD Cowen analyst Steve Scala maintained a Hold rating on Pfizer (PFE – Research Report) today and set a price target of $32.00. The company’s ...

So far this year, Pfizer shares have dropped 17.4%, while Novo Nordisk's stock has tumbled 24% and Lilly shares have slipped 3.2%. The SPDR S&P Pharmaceuticals ETF XPH has shed 12.1% year to date and ...